PRECIGEN, INC. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
PRECIGEN, INC. (PGEN) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $3.31 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-04
- PRECIGEN, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $3.31M, a 102.38% increase year-over-year.
- PRECIGEN, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $3.27M, a 22.19% increase year-over-year.
- PRECIGEN, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-12-31 was $2.42M, a 15.39% decline year-over-year.
- PRECIGEN, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $4.50M, a 118.29% increase year-over-year.
- PRECIGEN, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $11.24M, a 18.66% increase from fiscal 2024.
- PRECIGEN, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $9.47M, a 4.22% decline from fiscal 2023.
- PRECIGEN, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $9.89M, a 3.13% decline from fiscal 2022.
- PRECIGEN, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $10.21M, a 26.59% decline from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.31M 10-Q · filed 2026-08-04 | $6.59M 10-Q · filed 2026-08-04 | $9.01M derived: sum of 3 quarters · filed 2026-08-04 | $13.51M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $3.27M 10-Q · filed 2026-05-13 | $5.70M derived: sum of 2 quarters · filed 2026-05-13 | $10.19M derived: sum of 3 quarters · filed 2026-05-13 | $11.83M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $2.42M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $6.92M derived: sum of 2 quarters · filed 2026-03-25 | $8.56M derived: sum of 3 quarters · filed 2026-08-04 | $11.24M 10-K · filed 2026-03-25 |
| 2025-09-30 | $4.50M 10-Q · filed 2025-11-13 | $6.14M derived: sum of 2 quarters · filed 2026-08-04 | $8.81M 10-Q · filed 2025-11-13 | $11.68M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | $1.64M 10-Q · filed 2026-08-04 | $4.32M 10-Q · filed 2026-08-04 | $7.18M derived: sum of 3 quarters · filed 2026-08-04 | $9.24M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $2.68M 10-Q · filed 2026-05-13 | $5.54M derived: sum of 2 quarters · filed 2026-05-13 | $7.60M derived: sum of 3 quarters · filed 2026-05-13 | $9.57M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $2.87M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $4.93M derived: sum of 2 quarters · filed 2026-03-25 | $6.89M derived: sum of 3 quarters · filed 2026-03-25 | $9.47M 10-K · filed 2026-03-25 |
| 2024-09-30 | $2.06M 10-Q · filed 2025-11-13 | $4.03M derived: sum of 2 quarters · filed 2025-11-13 | $6.61M 10-Q · filed 2025-11-13 | $8.87M derived: sum of 4 quarters · filed 2026-03-25 |
| 2024-06-30 | $1.96M 10-Q · filed 2025-08-12 | $4.54M 10-Q · filed 2025-08-12 | $6.81M derived: sum of 3 quarters · filed 2026-03-25 | $9.11M derived: sum of 4 quarters · filed 2026-03-25 |
| 2024-03-31 | $2.58M 10-Q · filed 2025-05-14 | $4.84M derived: sum of 2 quarters · filed 2026-03-25 | $7.15M derived: sum of 3 quarters · filed 2026-03-25 | $9.34M derived: sum of 4 quarters · filed 2026-03-25 |
| 2023-12-31 | $2.26M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $4.57M derived: sum of 2 quarters · filed 2026-03-25 | $6.76M derived: sum of 3 quarters · filed 2026-03-25 | $9.89M 10-K · filed 2026-03-25 |
| 2023-09-30 | $2.31M 10-Q · filed 2024-11-14 | $4.49M derived: sum of 2 quarters · filed 2024-11-14 | $7.63M 10-Q · filed 2024-11-14 | $9.84M derived: sum of 4 quarters · filed 2025-03-19 |
| 2023-06-30 | $2.19M 10-Q · filed 2024-08-14 | $5.32M 10-Q · filed 2024-08-14 | $7.53M derived: sum of 3 quarters · filed 2025-03-19 | $9.65M derived: sum of 4 quarters · filed 2025-03-19 |
| 2023-03-31 | $3.13M 10-Q · filed 2024-05-14 | $5.34M derived: sum of 2 quarters · filed 2025-03-19 | $7.47M derived: sum of 3 quarters · filed 2025-03-19 | $9.78M derived: sum of 4 quarters · filed 2025-03-19 |
| 2022-12-31 | $2.21M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-19 | $4.34M derived: sum of 2 quarters · filed 2025-03-19 | $6.64M derived: sum of 3 quarters · filed 2025-03-19 | $10.21M 10-K · filed 2025-03-19 |
| 2022-09-30 | $2.13M 10-Q · filed 2023-11-09 | $4.43M derived: sum of 2 quarters · filed 2023-11-09 | $8.00M 10-Q · filed 2023-11-09 | $10.44M derived: sum of 4 quarters · filed 2024-03-19 |
| 2022-06-30 | $2.31M 10-Q · filed 2023-08-09 | $5.87M 10-Q · filed 2023-08-09 | $8.31M derived: sum of 3 quarters · filed 2024-03-19 | $10.80M derived: sum of 4 quarters · filed 2024-03-19 |
| 2022-03-31 | $3.56M 10-Q · filed 2023-05-10 | $6.00M derived: sum of 2 quarters · filed 2024-03-19 | $8.49M derived: sum of 3 quarters · filed 2024-03-19 | $12.05M derived: sum of 4 quarters · filed 2024-03-19 |
| 2021-12-31 | $2.44M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | $4.93M derived: sum of 2 quarters · filed 2024-03-19 | $8.49M derived: sum of 3 quarters · filed 2024-03-19 | $13.90M 10-K · filed 2024-03-19 |
| 2021-09-30 | $2.49M 10-Q · filed 2022-11-09 | $6.05M derived: sum of 2 quarters · filed 2022-11-09 | $11.46M 10-Q · filed 2022-11-09 | $15.96M derived: sum of 4 quarters · filed 2023-03-06 |
| 2021-06-30 | $3.56M 10-Q · filed 2022-08-08 | $8.97M 10-Q · filed 2022-08-08 | $13.47M derived: sum of 3 quarters · filed 2023-03-06 | $18.07M derived: sum of 4 quarters · filed 2023-03-06 |
| 2021-03-31 | $5.42M 10-Q · filed 2022-05-09 | $9.91M derived: sum of 2 quarters · filed 2023-03-06 | $14.51M derived: sum of 3 quarters · filed 2023-03-06 | $19.41M derived: sum of 4 quarters · filed 2023-03-06 |
| 2020-12-31 | $4.50M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | $9.10M derived: sum of 2 quarters · filed 2023-03-06 | $13.99M derived: sum of 3 quarters · filed 2023-03-06 | $18.37M 10-K · filed 2023-03-06 |
| 2020-09-30 | $4.60M 10-Q · filed 2021-11-08 | $9.50M derived: sum of 2 quarters · filed 2021-11-08 | $13.87M 10-Q · filed 2021-11-08 | $18.28M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | $4.90M 10-Q · filed 2021-08-09 | $9.27M 10-Q · filed 2021-08-09 | $13.68M derived: sum of 3 quarters · filed 2022-03-01 | $19.10M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | $4.37M 10-Q · filed 2021-05-10 | $8.78M derived: sum of 2 quarters · filed 2022-03-01 | $14.21M derived: sum of 3 quarters · filed 2022-03-01 | $14.27M derived: sum of 4 quarters · filed 2022-03-01 |
| 2019-12-31 | $4.41M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $9.84M derived: sum of 2 quarters · filed 2022-03-01 | $9.90M derived: sum of 3 quarters · filed 2022-03-01 | $18.95M 10-K · filed 2022-03-01 |
| 2019-09-30 | $5.42M 10-Q · filed 2019-11-12 | $5.48M derived: sum of 2 quarters · filed 2020-08-10 | $14.54M 10-Q · filed 2020-11-09 | $22.49M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-06-30 | $61.00K 10-Q · filed 2020-08-10 | $9.12M 10-Q · filed 2020-08-10 | $17.07M derived: sum of 3 quarters · filed 2021-03-01 | $25.20M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-03-31 | $9.05M 10-Q · filed 2020-05-11 | $17.01M derived: sum of 2 quarters · filed 2021-03-01 | $25.14M derived: sum of 3 quarters · filed 2021-03-01 | $33.99M derived: sum of 4 quarters · filed 2021-03-01 |
| 2018-12-31 | $7.96M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $16.09M derived: sum of 2 quarters · filed 2021-03-01 | $24.93M derived: sum of 3 quarters · filed 2021-03-01 | $36.30M 10-K · filed 2021-03-01 |
| 2018-09-30 | $8.13M 10-Q · filed 2019-11-12 | $16.98M derived: sum of 2 quarters · filed 2019-11-12 | $28.34M 10-Q · filed 2019-11-12 | |
| 2018-06-30 | $8.85M 10-Q · filed 2019-08-09 | $20.21M 10-Q · filed 2019-08-09 | ||
| 2018-03-31 | $11.36M 10-Q · filed 2019-05-09 | |||
| 2017-12-31 | $41.58M 10-K · filed 2020-03-02 | |||
| 2016-12-31 | $42.18M 10-K · filed 2019-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |